Skip to main content
Download PDF

Real-world predictors of changes in fear of COVID-19 in the Japanese general population: a large-scale internet-based cohort study with 20,712 participants

BMC Psychiatry volume 24, Article number: 435 (2024) Cite this article

Abstract

Background

Coronavirus disease 2019 (COVID-19) is a respiratory infection that considerably impacts both physical and mental health. In particular, the prolonged nature of psychological issues associated with COVID-19 has become a concern. However, evidence based on longitudinal studies investigating the changes in fear of COVID-19 has been limited, posing a public health challenge.

Methods

We investigated the predictors of changes in the Fear of COVID-19 Scale (FCV-19S) scores in the general Japanese population using data from a large-scale internet-based cohort study.

Results

We included 20,712 study participants (mean age = 51.1 years, percentage of males = 49.9%). The baseline FCV-19S score for the research participants was 17.0, and one year later, the FCV-19S score decreased to 15.8. The predictors of increase in FCV-19S scores were older age, male sex, COVID-19 requiring oxygen therapy, higher baseline FCV-19S total score, severe psychological distress, never married, worsening subjective health status, a greater number of COVID-19 vaccinations, a history of alcohol dependency, and living with family members. Conversely, the predictors of decrease in FCV-19S scores included habitual alcohol intake, COVID-19 not requiring oxygen therapy and a higher household income. Our study was an internet-based survey focused on residents of Japan, which raises the possibility of selection bias and makes it unclear whether the findings can be extrapolated to other countries and cultures.

Conclusion

During the observation period, the FCV-19S scores significantly decreased. Severe COVID-19 requiring oxygen therapy within one year of baseline was the most impactful predictor of an increase in FCV-19S score. On the other hand, mild COVID-19 not requiring oxygen therapy was a predictor of a decrease in FCV-19S scores. Therefore, we believe that it is necessary to adopt individualized approaches stratified by the severity of the infection when addressing the fear of COVID-19.

Peer Review reports

Background

Since the identification of coronavirus disease 2019 (COVID-19) in December 2019, the number of related deaths has continued to increase [1]. In the initial stages, the focus was on managing and treating physical conditions; however, gradually, mental health issues became more apparent [2]. Notably, with the increasing risk of COVID-19, there has been an increase in concerns related to anxiety and fear of COVID-19 [3]. Fear of the virus mutating, anxiety about an unknown illness, discrimination and prejudice due to COVID-19, and social isolation due to restrictive measures all imposed considerable psychological burdens on individuals [3]. Furthermore, the COVID-19 pandemic severely impacted the socioeconomic structure, leading to dysfunction [4]. Owing to these psychosocial stressors, there has been an increase in mental health disorders, including depression, anxiety and adjustment disorders during the COVID-19 pandemic regardless of region or age [5, 6]. Some cases escalate to the point of trauma, leading to long-term psychological consequences [7, 8].

In general, while many infections have acute and transient impacts, the psychological effects of COVID-19 persist, leading to heightened levels of fear and anxiety. In the early stages of the COVID-19 pandemic, mental health support was provided for healthcare workers involved in treatment of individuals infected with COVID-19 [9]. However, recently, stress responses in the general population during the pandemic have become a concern, irrespective of infection status, and research is underway on public health strategies [10]. Understanding the predictors of fear during the COVID-19 pandemic in the general population is valuable not only for academic pursuits but also for assisting in effective public health interventions and targeted mental health support. Previous studies have conducted cross-sectional surveys on factors related to fear during the COVID-19 pandemic [11,12,13]. However, there is insufficient evidence to assess the predictors of fear of COVID-19.

The primary objective of this study was to elucidate the predictors of changes in the Fear of COVID-19 Scale (FCV-19S) in the general Japanese population and to provide valuable insights into the factors influencing the trajectory of fear during the ongoing pandemic. We utilized data from a large-scale internet-based cohort study known as the Japan Society and New Tobacco Internet Survey (JASTIS), initiated in 2015 to explore the social impact of heated tobacco products [14, 15]. Following the onset of the COVID-19 pandemic, additional questions related to the impact of COVID-19 were incorporated, and annual surveys were performed. Therefore, the data obtained from the JASTIS are instrumental in investigating the predictors of fear in the general population during the COVID-19 pandemic. The FCV-19S was designed to measure individual levels of fear related to COVID-19 and served as a crucial tool in this survey [3, 16]. Building upon these societal backgrounds and research needs, we investigated the predictors of changes in fear during the COVID-19 pandemic in the general Japanese population using a longitudinal approach with the FCV-19S.

Methods

Study design and participants

This study used data from the large-scale online JASTIS [14]. JASTIS is a longitudinal study project that comprises a series of annual online surveys that have been undertaken since 2015. As of June 1, 2022, a total of eight survey waves have been conducted. In this study, we used data from the survey of the 2022 JASTIS, which was conducted from the 1st to 28th of February 2022, and from the 2023 JASTIS, which was conducted from the 6th to 27th of February 2023. Details of the JASTIS have been previously published [14].

Among the 33,000 respondents of JASTIS 2022, we initially screened all respondents and excluded individuals who met any of the following three criteria [17]: (1) Those who selected other than the second from the bottom in the question of “please select the second option from the bottom out of five options (A, B, C, D, and E)”; (2) Those who selected “yes” to all drug use (do you use the following drugs? alcohol, strong chu-hi with an alcohol content of 9% or more, sleeping pills/antianxiety medications, morphine, thinner, marijuana, dangerous drugs [e.g., outlawed herbs, magic mushrooms, etc.], and cocaine/husk [eight items]); (3) Those who selected “yes” to comorbidity of all diseases (do you have the following diseases? hypertension, diabetes, asthma, atopic dermatitis, allergic rhinitis, angina pectoris/myocardial infarction, stroke [cerebral infarction or cerebral hemorrhage], cancer/malignant tumor, and chronic pain [nine items]).

We excluded participants who had history of COVID-19 before baseline (JASTIS 2022). Finally, we excluded individuals who did not participate in JASTIS 2023.

Outcome measurement

We used the Japanese version of the FCV-19S. The FCV-19S is a brief self-report instrument that assesses an individual's level of fear of COVID-19 [3, 13]. It is frequently employed in both research and clinical environments to promptly recognize individuals who might be experiencing feelings of fear. It comprises seven items (e.g., ‘I am most afraid of Coronavirus‐19’), scored on a five‐item Likert‐type scale ranging from 1 (strongly disagree) to 5 (strongly agree). The scale scores range from 7 (minimum) to 35 (maximum), with higher scores indicating greater fear of COVID‐19. The validity and reliability of the Japanese version of the FCV-19S have been confirmed [16].

Exposure to COVID-19

Respondents were classified into three groups based on their exposure to COVID-19 during the follow-up period: those who were infected with COVID-19 and required oxygen therapy, those who were infected with COVID-19 but did not require oxygen therapy, and those who were not infected with COVID-19. Until May 8, 2023, when the classification of COVID-19 under the Infectious Disease Act was changed from a novel influenza infection to a class V infectious disease, all newly identified COVID-19 cases in Japan were required to be identified through the Notifiable Disease Surveillance System, and confirmation was primarily based on laboratory tests, primarily nucleic acid amplification tests.

Covariates

A broad set of 16 covariates in JASTIS 2022 that could be associated with the FCV-19S included the following: (1) sex, (2) age, (3) number of family members (1, 2, 3 or more), (4) marital status (married, never married, widowed, divorced), (5) employment (employer/self-employed, employee, student, homemaker, retired, unemployed), (6) education (high school or lower, college or higher), (7) habitual alcohol intake (not at all, 1 or fewer times per week, 2 or more times per week), (8) smoking status (nonsmoker, current smoker, former smoker), (9) home ownership, (10) number of COVID-19 vaccinations, (11) the Kessler Screening Scale for Psychological Distress (K6) score [18, 19], (12) adverse childhood experiences [20, 21] (0, 1 or more), (13) subjective health status (average, good, poor), (14) history of alcohol dependency, (15) history of depression, and (16) household income (Japanese yen (income < 4 million, 4 million ≤ income < 8 million, 8 million ≤ income, did not know/did not want to answer)). Although individuals with a missing value for any covariate were excluded from the regression analyses, a missing value category for income was used as a dummy variable (Did not know/Did not want to answer) because of the relatively large sample size.

Statistical analyses

The longitudinal approach is well suited for examining changes in fear of COVID-19. However, there is a possibility that participants may be lost to follow-up, potentially introducing bias into the results [22]. To address nonrandom nonresponses, we applied inverse probability weighting (IPW) to the remaining participants in each survey by modeling the probability of not dropping out from the study [23]. Given that considerable differences in baseline characteristics were observed between responders and nonresponders, we established a logistic regression model to account for nonresponsiveness [23]. This model incorporated potential confounding factors, including a nonresponse variable. The nonresponse variable was regarded as a key predictor of nonparticipation in the subsequent survey [24]. We conducted a multivariate logistic regression analysis to calculate propensity scores, which were used to predict the probability of completing follow-up. In our models, all 16 covariates and participation in JACSIS 2022 or not were included as independent variables.

For the JASTIS study, invitations for JASTIS 2023 were primarily sent to JASTIS 2022 participants. Additionally, invitations were extended to former Japan COVID-19 and Society Internet Survey (JACSIS) [25] participants due to the similarities in the JACSIS and JASTIS sample selection processes, with the aim of achieving the designated sample size. Participation data from JACSIS 2022 were not used in subsequent analyses. All the questionnaires were designed such that the respondents had to answer each question before they could proceed to the next question, thereby precluding the issue of missing data. The inclusion of additional covariates that could predict follow-up participation in the subsequent survey may effectively make the “assumption of missing at random” appropriate in the process of propensity score calculation [26].

The demographic and clinical characteristics of the respondents are presented as proportions for nominal variables and mean values with standard deviations for continuous variables. A paired t test was subsequently conducted to assess the statistical significance of the difference in means between the baseline and one-year FCV-19S scores. Multiple regression analysis with IPW was used to calculate the estimate, standard error, t value and p value for the predictors of changes in the FCV-19S total score. In the analysis, COVID-19 exposure, baseline FCV-19S total score and all 16 covariates were used as independent variables, while the difference between the baseline and one-year FCV-19S scores (“one-year FCV-19S total score” – “baseline FCV-19S total score”) for each study participant was used as the dependent variable. Probability values for the statistical tests were two-tailed, and p < 0.05 was considered to indicate statistical significance.

All the statistical analyses were performed with IBM SPSS Statistics (IBM Corporation, Version 28.0.0.0) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [27]. EZR provides a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 4.0.3). More precisely, EZR is a modified version of R Commander (version 2.7–1) that incorporates the statistical functions frequently used in biostatistics.

Ethical considerations

All participants responded to the online questionnaires after they provided online informed consent, and their intention to participate in this survey was confirmed. A credit point known as an “E-point,” which can be used for online shopping or converted to cash, was provided to the participants as an incentive. All procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki. This study was approved by the Institutional Review Board of the Osaka International Cancer Institute (approval number: 20084).

Results

In JASTIS 2022, 28,786 participants met the eligibility criteria; however, in JASTIS 2023, 8,074 participants dropped out. A total of 20,712 individuals were included in the final analysis (Fig. 1). The demographic characteristics of the study participants are presented in Table 1. The mean age of the research participants was 51.07 years, and the participants were 49.9% male and 50.1% female. The mean baseline FCV-19S total score was 17.01 (standard deviation = 5.49), and the mean FCV-19S total score one year later was 15.81 (standard deviation = 5.52). The results of the paired t test indicated a statistically significant difference in the mean FCV-19S score between baseline and one year later (p < 0.001).

Table 1 Clinical and demographic characteristics of study participants in final population for analysis
Full size table
Fig. 1
figure 1

Participant flow chart. In JASTIS 2022, 28,786 participants met the eligibility criteria; however, in JASTIS 2023, 8,074 participants dropped out. A total of 20,712 individuals were included in the final analysis

Full size image

The predictors of changes in the FCV-19S total score over the course of 1 year from baseline based on the multiple regression analysis with IPW are shown in Table 2. The results indicated that the predictors of increase in FCV-19S scores were older age (estimate = 0.02, p < 0.001), male sex (estimate = 0.21, p = 0.0038), COVID-19 requiring oxygen therapy (estimate = 2.95, p < 0.001), higher baseline FCV-19S total score (estimate = 0.59, p < 0.001), severe psychological distress (estimate = 0.44, p < 0.001), never married (estimate = 0.45, p < 0.001), worsening subjective health status (good = reference; average, estimate = 0.59, p < 0.001; poor, estimate = 0.76, p < 0.001), a greater number of COVID-19 vaccinations (n = 0, reference; n = 1, estimate = 0.97, p = 0.0062; n = 2, estimate = 0.41, p < 0.001; n = 3, estimate = 0.49, p < 0.001), a history of alcohol dependency (estimate = 0.53, p = 0.026), and living with family members (estimate = 0.26, p = 0.0066). Conversely, the predictors of a decreased FCV-19S score included habitual alcohol intake (1 or fewer times per week, estimate = -0.25, p = 0.0007; 2 or more times per week, estimate = -0.19, p = 0.018), COVID-19 not requiring oxygen therapy (estimate = -0.99, p < 0.001), and a higher household income (income < 4 million Japanese yen = reference; 4 million ≤ income < 8 million, estimate = -0.20, p = 0.018; 8 million ≤ income, estimate = -0.45, p < 0.001). The predictors of changes in the FCV-19S total score determined without IPW are shown in Table S1. There was no multicollinearity among the independent variables used in the multiple regression analysis with or without IPW.

Table 2 Predictors of changes in Fear of COVID-19 Scale based on multiple regression analysis with inverse probability weighting
Full size table

Discussion

This study showed that the FCV-19S total score one year later decreased in comparison to that of the baseline survey conducted in 2022. Consequently, there is speculation that the initial fear associated with the COVID-19 pandemic, feared as an unknown infectious disease, has waned over time owing to the implementation of infection prevention measures, enhanced support systems, and the widespread distribution of vaccines. On the other hand, individuals with higher baseline FCV-19S total scores tended to have even higher scores one year later. This finding suggested that those more susceptible to fear may experience a worsening of fear over time. Therefore, we believe that it is necessary to adopt individualized approaches stratified by the severity of the infection when addressing the fear of COVID-19.

In our study, severe COVID-19 requiring oxygen therapy within one year from baseline was the most impactful predictor of increase in FCV-19S scores one year later. This finding aligns with those of prior research suggesting that individuals with severe COVID-19 are more prone to manifesting long-term psychological symptoms, commonly referred to as long COVID symptoms [28]. Conversely, participants who had relatively mild COVID-19 and did not need oxygen therapy had significantly lower FCV-19S scores than did their uninfected counterparts. This outcome can be explained from a resilience standpoint [29]. Despite facing the fear of contracting COVID-19, individuals who do not experience severe psychological trauma and successfully recover may develop resistance to the fear associated with COVID-19. Based on these results, it has been proposed that the severity of COVID-19 may warrant adjustments in subsequent psychological support.

Moreover, the number of administered COVID-19 vaccines was a predictor of changes in fear of COVID-19. Although Japan is recognized for its high vaccination rate compared to that of the global population [30], it is possible that vaccination is carried out passively, influenced by fear and societal pressure. COVID-19 vaccines have the potential to diminish the risk of contracting and developing severe COVID-19 [31]. However, adverse events such as anaphylactic shock have also been documented [32]. Previous research has indicated that trust in vaccines is correlated with an increased willingness to be vaccinated [33]. It is crucial for individuals to seek reliable information, fully comprehend the associated risks and benefits, and make informed decisions regarding the necessity of vaccination.

Interestingly, our investigation revealed an inverse correlation between baseline income levels and changes in FCV-19S scores. Previous reports have suggested that the behavioral constraints imposed during the COVID-19 pandemic contributed to economic stagnation and increased societal poverty. Against the backdrop of the COVID-19 pandemic, characterized by an increasing prominence of mental health issues among citizens, individuals with lower incomes experienced more pronounced psychological distress [34]. Additionally, low income is not only a contributing factor to deteriorating mental health but is also linked to various socioeconomic vulnerabilities, including unemployment and housing instability [35]. Despite the Japanese government's efforts to provide one-time cash payments to support households, reports suggest that transient economic interventions may not substantially alter consumption behavior in contexts marked by heightened COVID-19-related anxiety and that their impacts may be constrained [12]. Therefore, we believe that it is crucial to establish a robust system ensuring stable employment, thereby empowering individuals to strategize for their future well-being from both mental health and socioeconomic perspectives.

Furthermore, habitual alcohol intake, compared to abstaining from alcohol entirely, was a predictor of decrease in FCV-19S scores. Previous research has indicated that moderate alcohol consumption has a calming effect on anxiety and depression [36]. Therefore, in the context of the unstable societal situation with the spread of emerging infectious diseases, moderate alcohol consumption was suggested to have a protective effect on mental health. On the other hand, a history of alcohol dependence was identified as a predictor of increase in FCV-19S scores. Alcohol dependence is often comorbid with other mental disorders, including depression, making it a major public health concern [37]. In fact, in this study, the presence of severe psychological distress emerged as a predictor of increase in FCV-19S scores. Lockdowns during the COVID-19 pandemic have been identified as a factor causing psychological distress, and further mental and physical issues may have emerged as a result of individuals attempting to self-treat this distress through excessive alcohol consumption [38]. Considering the risks and benefits of alcohol consumption, it might be advisable to refrain from drinking with the intention of alleviating the fear of COVID-19.

Notably, having never been married, compared to being married, was a statistically significant predictor of an increase in FCV-19S score. According to previous research, social isolation is known to be a risk factor for depression [39], and this trend was reported to persist during the COVID-19 pandemic [40]. Therefore, especially in situations where behavior is restricted, it was estimated that the increase in fear of COVID-19 for individuals in social isolation can be somewhat prevented by actively establishing support systems, including the use of online services [41]. On the other hand, cohabitation with family members was a predictor of increase in FCV-19S scores. This result contrasts with the expectation that living with family members would reduce the risk of social isolation and lead to decreased fear of COVID-19. Previous research has suggested that individuals may experience greater distress concerning their family members potentially contracting COVID-19 (or inadvertent transmission to others) than about their own infection [42]. Additionally, studies have reported heightened psychological distress among individuals cohabiting with elderly or handicapped family members during the COVID-19 pandemic [43]. Hence, the presence of vulnerable cohabiting family members who are susceptible to infection may indirectly contribute to an increased fear of COVID-19.

In this study, sex differences also emerged as predictors of changes in the FCV-19S score. Notably, in contrast to female sex, male sex was a predictor of increase in FCV-19S scores one year later. Intriguingly, certain prior studies have indicated a tendency for women to experience more pronounced fear of COVID-19 than men [44]. Furthermore, the impact of lockdown measures during the COVID-19 pandemic has been recognized as potentially rendering women more vulnerable to feelings of social isolation than men [45]. However, with the progression of COVID-19 countermeasures and the resumption of social interactions, the stress coping style of women may effectively function as a form of resilience against the fear of COVID-19 [46]. Notably, the societal conditions in this study, occurring 2–3 years after the onset of the pandemic, resulted in advancements in preventive measures and social support compared to those observed during the period when previous studies were conducted. These shifts in societal background could account for the discrepancies in results pertaining to sex differences in FCV-19S scores compared to earlier research.

Our study has several limitations. First, this study was conducted with a primary focus on Japanese residents, making it uncertain whether the findings can be extrapolated to other countries and cultures. Second, our reliance on internet-based surveys may have introduced selection bias into our data since low-income people or elderly people could be excluded from the data collection due to poor web access. Third, despite our efforts to account for potential confounding variables, the presence of unidentified or residual confounders could have influenced our study outcomes. Fourth, the independent variables used in this study were mainly general sociodemographic characteristics, which limits their applicability from a clinical perspective. We refrained from gathering detailed clinical characteristics due to feasibility concerns about the survey. Fifth, the presence or absence of oxygen therapy is an important factor in the severity classification of COVID-19 [47], but information on the level of care intensity needed was lacking in our study. Therefore, it is considered necessary to conduct surveys targeting medical institutions and to examine patient backgrounds in a clinical context, including post-COVID-19 rehabilitation. Finally, while our study has the epidemiological strength of a large sample size, there are limitations in its clinical impact. Thus, we aimed to conduct further research based on this study to investigate the clinical factors influencing the fear of COVID-19 and their causal relationships.

Conclusion

During the observation period, the FCV-19S scores significantly decreased. This was considered influenced by the implementation of measures to prevent COVID-19 and the enhancement of support systems. Contracting severe COVID-19 requiring oxygen therapy within one year of baseline was the most impactful predictor of an increase in the FCV-19S score. This finding suggested the possibility of a prolonged trauma response to a severe physical crisis. On the other hand, we found that mild COVID-19 not requiring oxygen therapy was a predictor of a decrease in FCV-19S score. Therefore, we believe that it is necessary to adopt individualized approaches stratified by the severity of the infection when addressing the fear of COVID-19.

Availability of data and materials

The data used in this study are not available in a public repository because they contain personally identifiable or potentially sensitive patient information. Based on the regulations for ethical guidelines in Japan, the Research Ethics Committee of the Osaka International Cancer Institute imposed restrictions on the dissemination of the data collected in this study. To request data, please contact the institutional review board of the ethics committee. The contact information for our ethics committee is as follows: the Research Ethics Committee of the Osaka International Cancer Institute; Chuo-ku, Otemae 3–1-69, Osaka, Japan, Postal Code 541–8567, Phone + 81–6-6945–1181.

Abbreviations

COVID-19:

The coronavirus disease 2019

FCV-19S:

The Fear of COVID-19 Scale

JASTIS :

Japan “Society and New Tobacco” Internet Survey

References

  1. WHO Coronavirus (COVID-19) dashboard. https://covid19.who.int/. Accessed 1 Feb 2024.

  2. Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. N Engl J Med. 2020;383(6):510–2.

    Article  CAS  PubMed  Google Scholar 

  3. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The fear of COVID-19 scale: development and initial validation. Int J Ment Health Addict. 2022;20:1537–45 United States: © The Author(s) 2020.

    Article  PubMed  Google Scholar 

  4. Buheji M, da Costa CK, Beka G, Mavric B, De Souza YL, da Costa Silva SS, Hanafi M, Yein TC. The extent of covid-19 pandemic socio-economic impact on global poverty. a global integrative multidisciplinary review. Am J Econ. 2020;10(4):213–24.

    Article  Google Scholar 

  5. Khubchandani J, Sharma S, Webb FJ, Wiblishauser MJ, Bowman SL. Post-lockdown depression and anxiety in the USA during the COVID-19 pandemic. J Public Health. 2021;43(2):246–53.

    Article  Google Scholar 

  6. Silva C, Fonseca C, Ferreira R, Weidner A, Morgado B, Lopes MJ, Moritz S, Jelinek L, Schneider BC, Pinho LG. Depression in older adults during the COVID-19 pandemic: a systematic review. J Am Geriatr Soc. 2023;71(7):2308–25.

    Article  PubMed  Google Scholar 

  7. Liu CH, Zhang E, Wong GTF, Hyun S. Factors associated with depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic: clinical implications for US young adult mental health. Psychiatry Res. 2020;290:113172.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, Ni SY, Mei H, Yuan K, Shi L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28:423–33 England: © 2022. The Author(s), under exclusive licence to Springer Nature Limited.

    Article  CAS  PubMed  Google Scholar 

  9. Greenberg N, Docherty M, Gnanapragasam S, Wessely S. Managing mental health challenges faced by healthcare workers during covid-19 pandemic. BMJ. 2020;368:m1211.

    Article  PubMed  Google Scholar 

  10. Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L, Chen-Li D, Iacobucci M, Ho R, Majeed A. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fitzpatrick KM, Harris C, Drawve G. Fear of COVID-19 and the mental health consequences in America. Psychol Trauma Theory Res Pract Policy. 2020;12(S1):S17.

    Article  Google Scholar 

  12. Immordino G, Jappelli T, Oliviero T, Zazzaro A. Fear of COVID-19 contagion and consumption: evidence from a survey of Italian households. Health Econ. 2022;31(3):496–507.

    Article  PubMed  Google Scholar 

  13. Lin CY, Hou WL, Mamun MA, Aparecido da Silva J, Broche-Pérez Y, Ullah I, Masuyama A, Wakashima K, Mailliez M, Carre A, et al. Fear of COVID-19 Scale (FCV-19S) across countries: measurement invariance issues. Nurs Open. 2021;8(4):1892–908.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tabuchi T, Shinozaki T, Kunugita N, Nakamura M, Tsuji I. Study profile: the Japan “society and new tobacco” internet survey (JASTIS): a longitudinal internet cohort study of heat-not-burn tobacco products, electronic cigarettes, and conventional tobacco products in Japan. J Epidemiol. 2019;29(11):444–50.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hori A, Tabuchi T, Kunugita N. The spread of heated tobacco product (HTP) use across various subgroups during 2015–16 and 2017–18 in Japan. Environ Health Prev Med. 2023;28:5.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Wakashima K, Asai K, Kobayashi D, Koiwa K, Kamoshida S, Sakuraba M. The Japanese version of the Fear of COVID-19 scale: reliability, validity, and relation to coping behavior. PLoS One. 2020;15(11):e0241958.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nishimura M, Asai K, Tabuchi T, Toyokura E, Kawai T, Miyamoto A, Watanabe T, Kawaguchi T. Association of combustible cigarettes and heated tobacco products use with SARS-CoV-2 infection and severe COVID-19 in Japan: a JASTIS 2022 cross-sectional study. Sci Rep. 2023;13(1):1120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, Walters EE, Zaslavsky AM. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32(6):959–76.

    Article  CAS  PubMed  Google Scholar 

  19. Furukawa TA, Kawakami N, Saitoh M, Ono Y, Nakane Y, Nakamura Y, Tachimori H, Iwata N, Uda H, Nakane H, et al. The performance of the Japanese version of the K6 and K10 in the World Mental Health Survey Japan. Int J Methods Psychiatr Res. 2008;17(3):152–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, Koss MP, Marks JS. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) study. Am J Prev Med. 1998;14(4):245–58.

    Article  CAS  PubMed  Google Scholar 

  21. Fujiwara T. Impact of adverse childhood experience on physical and mental health: a life-course epidemiology perspective. Psychiatry Clin Neurosci. 2022;76(11):544–51.

    Article  PubMed  Google Scholar 

  22. International Agency for Research on Cancer. IARC handbooks of cancer prevention tobacco control volume 13: evaluating the effectiveness of smoke-free policies. Lyon: WHO Press; 2009.

    Google Scholar 

  23. Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tabuchi T, Fujiwara T. Are secondhand smoke-related diseases of children associated with parental smoking cessation? Determinants of parental smoking cessation in a population-based cohort study. Prev Med. 2015;73:81–7.

    Article  PubMed  Google Scholar 

  25. Sasaki N, Tabuchi T, Fujiwara T, Nishi D. Adverse childhood experiences and living in the socially deprived areas in adulthood: a cross-sectional study of the nationwide data in Japan. BMC Public Health. 2023;23(1):1616.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147–77.

    Article  PubMed  Google Scholar 

  27. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

    Article  CAS  PubMed  Google Scholar 

  28. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Southwick SM, Bonanno GA, Masten AS, Panter-Brick C, Yehuda R. Resilience definitions, theory, and challenges: interdisciplinary perspectives. Eur J Psychotraumatol. 2014;5(1):25338.

    Article  Google Scholar 

  30. Rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by select country, territory, or region. https://www.statista.com/statistics/1194939/rate-covid-vaccination-by-county-worldwide/. Accessed 1 Feb 2024.

  31. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

    Article  CAS  PubMed  Google Scholar 

  32. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390–9.

    Article  CAS  PubMed  Google Scholar 

  33. Sugawara N, Yasui-Furukori N, Fukushima A, Shimoda K. Attitudes of medical students toward COVID-19 vaccination: who is willing to receive a third dose of the vaccine? Vaccines. 2021;9(11):1295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kikuchi H, Machida M, Nakamura I, Saito R, Odagiri Y, Kojima T, Watanabe H, Inoue S. Development of severe psychological distress among low-income individuals during the COVID-19 pandemic: longitudinal study. BJPsych Open. 2021;7(2):e50.

    Article  PubMed  Google Scholar 

  35. Hall LR, Sanchez K, da Graca B, Bennett MM, Powers M, Warren AM. Income differences and COVID-19: impact on daily life and mental health. Popul Health Manag. 2021;25(3):384–91.

    Article  PubMed  Google Scholar 

  36. Skogen JC, Harvey SB, Henderson M, Stordal E, Mykletun A. Anxiety and depression among abstainers and low-level alcohol consumers. The Nord-Trøndelag Health Study. Addiction. 2009;104(9):1519–29.

    Article  PubMed  Google Scholar 

  37. Castillo-Carniglia A, Keyes KM, Hasin DS, Cerdá M. Psychiatric comorbidities in alcohol use disorder. Lancet Psychiatry. 2019;6(12):1068–80.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Khantzian EJ, Albanese MJ. Understanding addiction as self medication: finding hope behind the pain. Lanham: Rowman and Littlefield Publishers; 2008.

  39. Courtin E, Knapp M. Social isolation, loneliness and health in old age: a scoping review. Health Soc Care Community. 2017;25(3):799–812.

    Article  PubMed  Google Scholar 

  40. Pietrabissa G, Simpson SG. Psychological consequences of social isolation during COVID-19 outbreak. Front Psychol. 2020;11:2201.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Rauschenberg C, Schick A, Goetzl C, Roehr S, Riedel-Heller SG, Koppe G, Durstewitz D, Krumm S, Reininghaus U. Social isolation, mental health, and use of digital interventions in youth during the COVID-19 pandemic: a nationally representative survey. Eur Psychiatry. 2021;64(1):e20.

    Article  PubMed  Google Scholar 

  42. Barzilay R, Moore TM, Greenberg DM, DiDomenico GE, Brown LA, White LK, Gur RC, Gur RE. Resilience, COVID-19-related stress, anxiety and depression during the pandemic in a large population enriched for healthcare providers. Transl Psychiatry. 2020;10(1):291.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Yoshioka T, Okubo R, Tabuchi T, Odani S, Shinozaki T, Tsugawa Y. Factors associated with serious psychological distress during the COVID-19 pandemic in Japan: a nationwide cross-sectional internet-based study. BMJ Open. 2021;11(7):e051115.

    Article  PubMed  Google Scholar 

  44. Alsharawy A, Spoon R, Smith A, Ball S. Gender differences in fear and risk perception during the COVID-19 pandemic. Front Psychol. 2021;12:689467.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Jo H, Baek E-M. Social isolation in COVID-19: a comparative study between Korea and Vietnam. BMC Public Health. 2023;23(1):1556.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Matud MP. Gender differences in stress and coping styles. Pers Individ Differ. 2004;37(7):1401–15.

    Article  Google Scholar 

  47. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/. Accessed 29 May 2024.

Download references

Acknowledgements

We would like to thank the JASTIS team for their support with the data collection.

Funding

Our study was supported by Health Labor Sciences Research Grants (19FA1005, 19FA1012, 19FG2001, 20F1005, 20FA2001, 20EA1017, 21HA2016, 22FA1001, 22FA1002, 22FA1010, 22FA2001, 22FA1005, and 23FA1004), the Japan Society for the Promotion of Science (JSPS) KAKENHI Grants (19K13704, 19H01073, 19H01074, 20H00040, 20K10467, 21H03203, 21H04856), a JST Grant (JPMJPF2017), the intramural fund of the National Institute for Environmental Studies and the research program titled “Using Health Metrics to Monitor and Evaluate the Impact of Health Policies” conducted at the Tokyo Foundation for Policy Research.

Author information

Authors and Affiliations

  1. Department of Neuropsychiatry, Towada City Hospital, Towada, Aomori, Japan

    Keita Tokumitsu

  2. Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan

    Keita Tokumitsu, Norio Sugawara & Norio Yasui-Furukori

  3. Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan

    Takahiro Tabuchi

  4. Tokyo Foundation for Policy Research, Tokyo, Japan

    Takahiro Tabuchi

Authors
  1. Keita Tokumitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norio Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Tabuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norio Yasui-Furukori
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KT wrote the first draft of the manuscript and prepared all the tables. KT and NS performed the statistical analyses. NS and TT contributed to the conception and design of the work. TT was involved in the data acquisition. NS, TT and NYF contributed to the critical review of the manuscript. All the authors approved the final version of the manuscript.

Corresponding author

Correspondence to Norio Sugawara.

Ethics declarations

Ethics approval and consent to participate

All participants responded to the online questionnaires after they provided online informed consent, and their intention to participate in this survey was confirmed. A credit point known as an “E-point,” which can be used for online shopping or converted to cash, was provided to the participants as an incentive. All procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki. This study was approved by the Institutional Review Board of the Osaka International Cancer Institute (approval number: 20084).

Consent for publication

Not applicable.

Competing interests

KT, NS and TT have no conflicts of interest. NYF has received grant/research support or honoraria from and received speaker's honoraria from Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, MSD, and Otsuka Pharmaceutical. The companies had no role in the study design, the data collection or analysis, the decision to publish, or the preparation of the manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tokumitsu, K., Sugawara, N., Tabuchi, T. et al. Real-world predictors of changes in fear of COVID-19 in the Japanese general population: a large-scale internet-based cohort study with 20,712 participants. BMC Psychiatry 24, 435 (2024). https://doi.org/10.1186/s12888-024-05899-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12888-024-05899-6

Keywords

BMC Psychiatry

ISSN: 1471-244X

Contact us